Menu

Delphine CHARVIN

GENÈVE

En résumé

Fascinated by brain and mind, I have been working in Neurosciences for more than 10 years. I have always been interested in understanding the biological mechanisms of brain functions and cognition. Innovative and curious, I am recognized as a rigorous scientist and a project manager with strong leadership and organizational skills.

Combining a background in genetics, bioinformatics, neurosciences, drug discovery, project management and excellent adaptability skills, I am accustomed to diversity and relationships within cross-functional and multi-cultural environments.

Specialties and interests: neurosciences, drug discovery, project management, science of the brain and mind, education and human development.

Mes compétences :
R&D
Industrie pharmaceutique
Gestion de projet
Neurosciences
Management
Conseil
Leadership
Pharmacologie
GPCR
Drug discovery

Entreprises

  • Centre de Recherches Interdisciplinaires - Paris (CRI) - Scientific sponsor

    2015 - maintenant Scientific educator for "Les Savanturiers du Cerveau" 2015/2016.

    I am committed to guide a CM1/CM2 class (French "cycle 3", 9-11 years old) in their Research Project in Cognitive Sciences.

  • Frontiers in Pharmacology - Editorial Board Member

    2015 - maintenant

  • Prexton Therapeutics - Senior Director, Head of R&D

    2015 - maintenant I have been working at Prexton Therapeutics since its inception in 2012. I am responsible for all scientific activities, collaborations with academic and industry partners and for strategic decisions aiming at developing the most appropriate compound to treat motor symptoms of Parkinson’s disease and delay appearance of Levodopa-Induced Dyskinesia (LID) in patients.

  • Mindeed consulting - Founder and consultant

    2015 - maintenant

  • Prexton Therapeutics - Head of R&D

    2014 - 2015
    - Responsible of establishing a high-quality scientific frame and project leadership for the project team and company board.
    - Management of cross-functional teams, all over the world (America, Europe, Asia).
    - Rapid progression of the project from Lead-Optimization phase to Pre-Clinical Candidate selection in 15 months, with major improvements in drug profile.

  • Prexton Therapeutics - Head of Biology

    2012 - 2014

  • Merck-Serono - Senior Scientist and Project Leader

    Lyon 2010 - 2012 - Build-up and management of a Parkinson’s disease in vitro pharmacology laboratory. Establishment of state-of-the-art technologies and assay capabilities.
    - Coordination of external in vitro profiling activities for a clinical Phase III PD program.
    - Proposal of a new discovery target for Parkinson’s disease to the senior decision making committees. Management of the project from Target Validation to Hit-To-Lead phases, and of the cross-functional and multi-cultural project team (3 international geographical sites).

  • Addex Pharmaceuticals - Laboratory Head, Project Leader

    2008 - 2010 - Enlargement of assays capability of the In Vitro Pharmacology Group of the Central Nervous System business unit, with the setting-up of primary cultures of native cells (neurons and glial cells).
    - Progression of two projects from Hit-To-Lead to the late Lead-Optimization phases (6 months before clinical candidate selection).
    - Proposal of a new discovery target for Schizophrenia. Management of the project from Target Proposal to Hit Selection phases.
    - Publication of 3 articles and 8 posters presented at international congresses.

  • EPFL - Post-doctorate, Laboratory of Pr Aebischer

    2006 - 2007 - Demonstration of a therapeutic effect of polyphenols-enriched diet in a mouse model of Amyotrophic Lateral Sclerosis.
    - Proposal and initiation of a project to create a viral-mediated rodent model of Alzheimer’s disease.
    - Collaboration with PhD students of the lab on other projects (PD, Adrenoleukodystrophy).
    - Publication of 1 article

  • Université Pierre et marie Curie - PhD

    2002 - 2005 - Demonstration of an effect of dopamine oxidation and D2 receptor stimulation in mutated huntingtin-induced neurotoxicity in vitro.
    - Demonstration of a neuroprotective effect of haloperidol, a D2 receptor antagonist, in a rat model of Huntington’s disease.
    - Collaboration with PhD students of the lab on other projects (drug addiction).
    - Publication of 4 articles, 2 reviews, 1 book chapter and 8 posters presented at international congresses.
    - Reward from the French Society of Neurosciences.

  • Université Paris 13 - Assistant Lecturer

    2002 - 2005 Neurobiology lessons and practice exams for scientist students. Weekly basis.

  • Inserm - Research student

    PARIS 13 2001 - 2002 - First characterization of the spastin protein, responsible for the most common form of Hereditary Spastic Paraplegia (HSP)
    - Creation of a genetic mouse model of HSP (Cre/LoxP strategy)
    - Publication of 2 articles and 2 posters presented at international congresses

  • Aventis Pharma - Laboratory Technician

    Antony 2000 - 2000 - Technical improvement and use of High Performance Liquid Chromatography (HPLC) to characterize the molecular effect of fungicidal inhibitors on Candida albicans

Formations

  • Ecole Polytechnique Fédérale De Lausanne (EPFL) (Lausanne)

    Lausanne 2006 - 2007 Post-doctorat

  • Université Pierre Et Marie Curie Paris 6 (UPMC) (Paris)

    Paris 2002 - 2005 Doctorat

    Dissertation: “Dopamine and striatal neurodegeneration in Huntington’s disease: towards the identification of new therapeutic targets”
    "Very Honorable" mention, Award for the best thesis in Neuroscience of the year (from the French Society of Neuroscience)

  • Université Paris 6 Pierre Et Marie Curie DEA de Neurosciences

    Paris 2001 - 2002 Neurosciences

  • Université D'Evry Val D'Essonne, Genopole

    Evry 1999 - 2001 Licence

  • Lycée Francois 1er

    Fontainebleau 1997 - 1999 Classes Préparatoires

Réseau

Annuaire des membres :